Kenichi Nakamura

10.8k total citations · 5 hit papers
203 papers, 6.8k citations indexed

About

Kenichi Nakamura is a scholar working on Physiology, Oncology and Surgery. According to data from OpenAlex, Kenichi Nakamura has authored 203 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Physiology, 52 papers in Oncology and 50 papers in Surgery. Recurrent topics in Kenichi Nakamura's work include Telomeres, Telomerase, and Senescence (42 papers), Gastric Cancer Management and Outcomes (27 papers) and Esophageal Cancer Research and Treatment (19 papers). Kenichi Nakamura is often cited by papers focused on Telomeres, Telomerase, and Senescence (42 papers), Gastric Cancer Management and Outcomes (27 papers) and Esophageal Cancer Research and Treatment (19 papers). Kenichi Nakamura collaborates with scholars based in Japan, United States and Canada. Kenichi Nakamura's co-authors include Haruhiko Fukuda, Kaiyo Takubo, Tomio Arai, Tetsuya Mitsudomi, Masahiro Tsuboi, Kenji Suzuki, Hisao Asamura, Naotaka Izumiyama‐Shimomura, Hiroyuki Ito and Masayuki Shinoda and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Kenichi Nakamura

189 papers receiving 6.7k citations

Hit Papers

A Randomized Trial Comparing Postoperative Adjuvant Chemo... 2011 2026 2016 2021 2011 2022 2015 2019 2020 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
    2011 1.1k citations Nobutoshi Ando, Hoichi Kato et al. profile →
  2. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
    2022 764 citations Morihito Okada, Masashi Wakabayashi et al. profile →
  3. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria
    2015 603 citations Hiroshi Katayama, Kenichi Nakamura et al. profile →
  4. Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial
    2019 310 citations Morihito Okada, Junki Mizusawa et al. profile →
  5. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer
    2020 198 citations Masashi Wakabayashi, Kenichi Nakamura et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenichi Nakamura Japan 36 3.3k 2.5k 1.4k 1.4k 840 203 6.8k
Toshimasa Tsujinaka Japan 44 4.6k 1.4× 4.0k 1.6× 1.4k 1.0× 1.8k 1.3× 1.7k 2.0× 297 8.9k
William E. Lawson United States 44 4.1k 1.2× 1.0k 0.4× 1.4k 1.0× 304 0.2× 1.5k 1.7× 124 7.2k
Shuji Takiguchi Japan 57 4.7k 1.4× 4.8k 1.9× 858 0.6× 2.5k 1.8× 2.5k 3.0× 432 11.1k
Serge Adnot France 65 8.0k 2.4× 1.5k 0.6× 2.8k 2.0× 604 0.4× 2.9k 3.4× 215 12.4k
Gert Mayer Austria 48 2.2k 0.7× 2.6k 1.0× 619 0.4× 963 0.7× 1.5k 1.8× 330 9.1k
Jason C. Kovacic United States 52 1.4k 0.4× 2.3k 0.9× 938 0.7× 379 0.3× 2.6k 3.1× 212 8.3k
Benjamin A. Rybicki United States 48 4.8k 1.4× 681 0.3× 5.3k 3.8× 598 0.4× 2.1k 2.4× 161 10.0k
Calogero Saieva Italy 40 983 0.3× 1.2k 0.5× 266 0.2× 1.3k 0.9× 894 1.1× 204 5.2k
Christian Brambilla France 57 2.6k 0.8× 700 0.3× 839 0.6× 2.8k 2.0× 3.7k 4.4× 169 8.3k
Jian Chen China 36 682 0.2× 684 0.3× 484 0.3× 1.3k 0.9× 1.4k 1.7× 238 4.7k

Countries citing papers authored by Kenichi Nakamura

Since Specialization
Citations

This map shows the geographic impact of Kenichi Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenichi Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenichi Nakamura more than expected).

Fields of papers citing papers by Kenichi Nakamura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenichi Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenichi Nakamura. The network helps show where Kenichi Nakamura may publish in the future.

Co-authorship network of co-authors of Kenichi Nakamura

This figure shows the co-authorship network connecting the top 25 collaborators of Kenichi Nakamura. A scholar is included among the top collaborators of Kenichi Nakamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenichi Nakamura. Kenichi Nakamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yamamoto, Shun, Ken Kato, Hiroyuki Daiko, et al.. (2024). Factors influencing decision-making between surgery and chemoradiotherapy for esophageal carcinoma from the JCOG0502. Future Oncology. 20(36). 2849–2854. 1 indexed citations
3.
Nishikawa, Tadaaki, Shigeki Kakunaga, Kenji Tamura, et al.. (2024). Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). Cancer. 130(22). 3836–3844. 2 indexed citations
4.
Niho, Seiji, Jun Sato, Miyako Satouchi, et al.. (2024). Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial. Lung Cancer. 191. 107557–107557. 6 indexed citations
5.
Ohba, Akihiro, Chigusa Morizane, Yasuyuki Kawamoto, et al.. (2024). Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of Clinical Oncology. 42(27). 3207–3217. 20 indexed citations
6.
Koyama, Takafumi, Toshio Shimizu, Yuki Kojima, et al.. (2023). Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study. Cancer Discovery. 13(8). 1814–1825. 25 indexed citations
7.
Okuma, Hitomi Sumiyoshi, Hiroshi Yoshida, Yoshihisa Kobayashi, et al.. (2023). Molecular pathology quality control in Southeast Asia: Results of a multiregional quality assurance study from MASTER KEY Asia. Cancer Science. 114(6). 2664–2673. 4 indexed citations
8.
Okuma, Hitomi Sumiyoshi, Kenji Tsuchihashi, Ryunosuke Machida, et al.. (2023). Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial). Clinical Cancer Research. 29(24). 5079–5086. 7 indexed citations
9.
Chino, Yasumasa, Xinsheng Huang, Isao Nakatsugawa, et al.. (2023). Research for application of newly-developed magnesium alloy sheet to front hood of automobiles. Journal of Japan Institute of Light Metals. 73(4). 168–174. 1 indexed citations
10.
Shimoi, Tatsunori, Kuniko Sunami, Natsuko Okita, et al.. (2023). Progress report of a cross‐organ and biomarker‐based basket‐type clinical trial: BELIEVE Trial. Cancer Science. 115(2). 555–563. 5 indexed citations
11.
Masaki, Chie, Kiminori Sugino, Yoshinori Tanizawa, et al.. (2022). Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study. Drugs - Real World Outcomes. 10(1). 145–158. 3 indexed citations
12.
Kato, Ken, Yoshinori Ito, Isao Nozaki, et al.. (2021). Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 161(6). 1878–1886.e2. 62 indexed citations
13.
Shide, Kotaro, Takuro Kameda, Ayako Kamiunten, et al.. (2020). Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood. 136(1). 106–118. 10 indexed citations
14.
15.
Miyamoto, Ken‐ichi, Atsuo Takashima, Junki Mizusawa, et al.. (2019). Efficacy of aspirin for stage III colorectal cancer: a randomized double-blind placebo-controlled trial (JCOG1503C, EPISODE-III trial). Japanese Journal of Clinical Oncology. 49(10). 985–990. 6 indexed citations
16.
Aida, Junko, Naotaka Izumiyama‐Shimomura, Kenichi Nakamura, et al.. (2018). Changes in telomere length with aging in human neurons and glial cells revealed by quantitative fluorescence in situ hybridization analysis. Geriatrics and gerontology international. 18(10). 1507–1512. 21 indexed citations
17.
Okuno, Tatsuya, Masashi Wakabayashi, Ken Kato, et al.. (2017). Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). International Journal of Clinical Oncology. 22(6). 1042–1049. 31 indexed citations
18.
19.
Terai, Masanori, Naotaka Izumiyama‐Shimomura, Junko Aida, et al.. (2013). Association of telomere shortening in myocardium with heart weight gain and cause of death. Scientific Reports. 3(1). 2401–2401. 34 indexed citations
20.
Takeuchi, Fujio, Shinji Harihara, Kenichi Nakamura, et al.. (2003). The mitochondrial DNA A3243G mutation in Werner's syndrome. Experimental Gerontology. 38(3). 339–342. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshimasa Tsujinaka Breakdown of academic impact, for papers by William E. Lawson Breakdown of academic impact, for papers by Shuji Takiguchi Breakdown of academic impact, for papers by Serge Adnot Breakdown of academic impact, for papers by Gert Mayer Breakdown of academic impact, for papers by Jason C. Kovacic Breakdown of academic impact, for papers by Benjamin A. Rybicki Breakdown of academic impact, for papers by Calogero Saieva Breakdown of academic impact, for papers by Christian Brambilla Breakdown of academic impact, for papers by Jian Chen
Rankless by CCL
2026